STRO Sutro Biopharma, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 12, 2026
$15,35
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$0,7752 haftanın en düşüğü
$43,8552 haftanın en yükseği
Piyasa Değeri (MRQ)
$254M
P/E (TTM)
-0.6
Hisse Başına Kâr (TTM)
$-26.71
Gelir (TTM)
$46M
rozetleriniz
52 Haftlık Aralık
$1–$44
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$47
P/E
-0.6
ROE
266.8%
Net Kâr Marjı
-395.2%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
STRO Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$15.35
Piyasa Değeri (MRQ)
$254M
P/E (TTM)
-0.6
Hisse Başına Kâr (TTM)
$-26.71
Gelir (TTM)
$46M
ROE (TTM)
266.8%
52 Haftlık Aralık
$1–$44
STRO Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 03 Aralık 2025 | 1-for-10 | Ters |
Sutro Biopharma, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar128
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$102M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-22.492020-12-31 → 2025-12-31
Serbest Nakit Akışı·2018-12-31 → 2018-12-31
Net kar marjı-395.2%2018-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | STRO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -0.65Y ort. ≈-2.6 | ≈-2.6 | · | · | |
| F/S (TTM) | 5.65Y ort. ≈4.6 | ≈4.6 | 48.5 | Düşük değerli | |
| F/D (MRQ) | -2.55Y ort. ≈1.9 | ≈1.9 | · | · | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -0.75Y ort. ≈23.8 | ≈23.8 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 4.55Y ort. ≈2.5 | ≈2.5 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | STRO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -319.6%5Y ort. ≈-189.3% | ≈-189.3% | -871.1% | En üst düzey | |
| FAVÖK Marjı (TTM) | -306.3%5Y ort. ≈-181.4% | ≈-181.4% | -871.1% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | -395.5%5Y ort. ≈-194.8% | ≈-194.8% | -196.5% | Zayıf | |
| Net Kâr Marjı (TTM) | -395.2%5Y ort. ≈-193.8% | ≈-193.8% | -871.2% | En üst düzey | |
| ROA (TTM) | -79.1%5Y ort. ≈-41.2% | ≈-41.2% | -39.4% | Zayıf | |
| ROE (TTM) | 266.8%5Y ort. ≈-46.8% | ≈-46.8% | -45.3% | En üst düzey | |
| ROIC | 119.5%5Y ort. ≈-136.8% | ≈-136.8% | -19.2% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | STRO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 3.35Y ort. ≈3.9 | ≈3.9 | 6.3 | Düşük likidite | |
| Cari Oran (MRQ) | 3.25Y ort. ≈3.4 | ≈3.4 | 4.9 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | STRO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 65.2%5Y ort. ≈37.3% | ≈37.3% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 14.8%5Y ort. ≈22.7% | ≈22.7% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 19.1% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | STRO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.45Y ort. ≈0.2 | ≈0.2 | 0.0 | En üst düzey | |
| Receivables Turnover (Alacak Devir Hızı) | 16.35Y ort. ≈8.0 | ≈8.0 | 3.9 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$800.7K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-3.4%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 5, 2026 | $-2.33 | $-2.24 | -4.1% |
| 31 Mart 2026 | May 14, 2026 | $-2.94 | $-3.85 | 23.6% |
| 31 Aralık 2025 | $-5.29 | $-4.43 | -19.4% | |
| 30 Eylül 2025 | $-6.70 | $-4.23 | -58.5% | |
| 30 Haziran 2025 | $-1.40 | $-4.10 | 65.9% | |
| 31 Mart 2025 | $-9.10 | $-7.22 | -26.1% | |
| 31 Aralık 2024 | $-8.90 | $-8.48 | -5.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-15.43 | $0.54 | $2.45 | $3.77 | $5.45 | $7.26 | · | $5.76 | · | |
| Revenue / Share | $12.06 | $0.81 | $2.56 | $1.34 | · | · | · | · | · | |
| Cash Flow / Share | $-20.86 | $-2.49 | $-1.86 | $0.07 | · | · | · | · | · | |
| Cash / Share | $6.77 | $2.31 | $1.14 | $0.82 | $0.66 | $4.51 | · | $5.48 | · | |
| EPS (TTM) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $25M | $28M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $32M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $46M | $47M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-21M | $-19M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-19M | $-24M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $2M | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-19M | $-26M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.37 | $-0.55 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.37 | $-0.55 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | · | 84,869,864 | 8,511,985 | 8,364,294 | · | 82,043,671 | 81,224,628 | 61,457,793 | · | 60,599,025 | 60,339,475 | 58,723,432 | 52,345,732 | 46,957,196 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | · | 84,869,864 | 8,511,985 | 8,364,294 | · | 82,043,671 | 81,224,628 | 61,457,793 | · | 60,599,025 | 60,339,475 | 58,723,432 | 52,345,732 | 46,957,196 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | $-21M | $-19M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $97M | $79M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | $191M | $113M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | $11M | $98M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | $11M | $8M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | $347M | $332M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | $24M | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | $2M | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | $401M | $386M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | $12M | $13M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | $10M | $8M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | $58M | $45M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | $31M | $32M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | $133.0K | $142.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | $171M | $177M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | $10M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | $55.0K | $49.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | $-418M | $-399M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | $-1M | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $230M | $209M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | $401M | $386M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | 54,631,360 | 48,674,232 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $7M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $66M | $-3M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-78M | $48M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $30M | $5M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $18M | $50M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | -84.3% | -69.0% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | -77.5% | -92.6% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | -77.5% | -83.7% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | -84.3% | -69.0% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | -5.1% | -7.0% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | -7.6% | -10.1% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | -9.8% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | 5.9 | 7.4 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | 5.1 | 6.5 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | 2.1 | 0.5 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-6.23 | $-4.04 | · | $-1.03 | $-0.38 | $-0.31 | · | $1.35 | $1.86 | $1.57 | · | $1.84 | $2.56 | $3.08 | $4.21 | $4.29 | |
| Revenue / Share | $0.59 | $1.11 | · | $0.11 | $0.75 | $0.21 | · | $0.10 | $0.32 | $0.21 | · | $0.28 | $0.17 | $0.22 | $0.48 | $0.60 | |
| Cash Flow / Share | · | $-3.23 | · | · | · | $-0.82 | · | · | · | $-1.05 | · | · | · | $-1.04 | · | · | |
| Cash / Share | $3.28 | $4.45 | · | $0.77 | $0.76 | $1.26 | · | $2.12 | $1.11 | $1.04 | · | $1.34 | $3.89 | $1.04 | $1.77 | $1.63 | |
| EPS (TTM) | $-26.71 | $-25.73 | · | $-38.73 | $-38.65 | $-37.89 | · | $-1.25 | $-1.47 | $-1.52 | · | $-2.89 | $-2.45 | $-2.36 | $-2.59 | $-2.89 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $46M | $100M | · | $106M | $104M | $66M | · | $161M | $169M | $154M | · | $49M | $57M | $75M | $70M | $53M | |
| Net Income TTM | $-181M | $-154M | · | $-217M | $-209M | $-245M | · | $-124M | $-124M | $-115M | · | $-172M | $-143M | $-130M | $-123M | $-134M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | $303M | $254M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | $72M | |
| P/E | -1.2 | -1.0 | · | -0.0 | -0.0 | -0.0 | · | -2.8 | -2.0 | -3.7 | · | -1.2 | -1.9 | -2.0 | -2.1 | -1.8 | |
| P/S | 12.0 | 4.1 | · | 0.7 | 0.6 | 0.8 | · | 1.8 | 1.4 | 2.3 | · | 4.3 | 4.9 | 3.7 | 4.3 | 4.8 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | 1.3 | 1.2 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | 1.3 | 1.2 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | 1.3 | |
| Earnings Yield | -80.5% | -103.3% | · | -4451.7% | -5443.7% | -5829.2% | · | -36.1% | -50.2% | -26.9% | · | -83.3% | -52.7% | -51.1% | -46.7% | -55.5% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $102M | $62M | $154M | $68M | $62M |
| Faaliyet Kâr Marjı % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Net Gelir | $-191M | $-227M | $-107M | $-119M | $-106M |
| Seyreltilmiş Hisse Başı Kâr | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | · | · | 0.0 | 0.1 | 0.1 |
| Cari Oran | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Cari Oran | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
Bu beyan için veri yok
Bu beyanı oluşturmak için henüz yeterli temel verisi yok.
Kurumsal Sahipler (13F) 110 dosya · $537.9M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
110
Tutulan Değer
$537.9M
Yeni pozisyonlar
43
Çıkan pozisyonlar
16
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 43 (+15 önceki Ç'ye göre) | 16 (+8 önceki Ç'ye göre) | 23 (+1 önceki Ç'ye göre) | 19 (+6 önceki Ç'ye göre) | +2.1M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43.320.887 | 1.304.846 | 8,05% | Hisse senetleri |
| BVF INC/IL | $41.559.362 | 1.251.788 | 7,73% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $38.926.568 | 1.172.487 | 7,24% | Hisse senetleri |
| BlackRock, Inc. | $37.272.146 | 1.122.655 | 6,93% | Hisse senetleri |
| SAMSARA BIOCAPITAL, LLC | $35.287.350 | 1.062.872 | 6,56% | Hisse senetleri |
| Kynam Capital Management, LP | $28.968.926 | 872.558 | 5,39% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $24.698.941 | 743.944 | 4,59% | Hisse senetleri |
| Balyasny Asset Management L.P. | $23.610.578 | 711.162 | 4,39% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.048.071 | 694.219 | 4,28% | Hisse senetleri |
| EVENTIDE ASSET MANAGEMENT, LLC | $19.430.698 | 585.262 | 3,61% | Hisse senetleri |
| Velan Capital Investment Management LP | $17.003.712 | 512.160 | 3,16% | Hisse senetleri |
| Woodline Partners LP | $15.206.563 | 458.029 | 2,83% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $13.413.265 | 404.014 | 2,49% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $12.940.982 | 389.692 | 2,41% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $12.150.270 | 365.972 | 2,26% | Hisse senetleri |
| STATE STREET CORP | $10.158.503 | 305.979 | 1,89% | Hisse senetleri |
| Merck & Co., Inc. | $9.042.053 | 272.351 | 1,68% | Hisse senetleri |
| ACUTA CAPITAL PARTNERS, LLC | $8.972.333 | 270.251 | 1,67% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $8.123.011 | 244.669 | 1,51% | Hisse senetleri |
| Point72 Asset Management, L.P. | $7.895.856 | 237.827 | 1,47% | Hisse senetleri |
| KVP Capital Advisors, LP | $7.522.290 | 226.575 | 1,40% | Hisse senetleri |
| UBS Group AG | $6.922.599 | 208.512 | 1,29% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $6.696.042 | 201.688 | 1,24% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.559.058 | 197.562 | 1,22% | Hisse senetleri |
| MARSHALL WACE, LLP | $5.818.167 | 175.246 | 1,08% | Hisse senetleri |
| Nuveen, LLC | $5.577.500 | 167.997 | 1,04% | Hisse senetleri |
| JPMORGAN CHASE & CO | $5.323.560 | 159.627 | 0,99% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $4.953.971 | 149.216 | 0,92% | Hisse senetleri |
| VANGUARD GROUP INC | $4.347.844 | 375.786 | 0,81% | Hisse senetleri |
| NORTHERN TRUST CORP | $4.180.976 | 125.933 | 0,78% | Hisse senetleri |
| Seven Fleet Capital Management LP | $3.794.182 | 159.118 | 0,71% | Hisse senetleri |
| Qube Research & Technologies Ltd | $3.539.452 | 106.610 | 0,66% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $3.460.502 | 104.232 | 0,64% | Hisse senetleri |
| CITADEL ADVISORS LLC | $3.385.238 | 101.965 | 0,63% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $3.146.264 | 94.767 | 0,58% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $2.865.957 | 86.324 | 0,53% | Hisse senetleri |
| Invesco Ltd. | $1.902.526 | 57.305 | 0,35% | Hisse senetleri |
| Y-Intercept (Hong Kong) Ltd | $1.855.183 | 55.879 | 0,34% | Hisse senetleri |
| Squarepoint Ops LLC | $1.843.895 | 55.539 | 0,34% | Hisse senetleri |
| XTX Topco Ltd | $1.732.011 | 52.169 | 0,32% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.636.826 | 49.302 | 0,30% | Hisse senetleri |
| Sigma Planning Corp | $1.494.664 | 45.020 | 0,28% | Hisse senetleri |
| Bank of New York Mellon Corp | $1.373.451 | 41.369 | 0,26% | Hisse senetleri |
| BARCLAYS PLC | $1.226.872 | 36.954 | 0,23% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $1.199.848 | 36.140 | 0,22% | Hisse senetleri |
| Fisher Asset Management, LLC | $1.171.794 | 35.295 | 0,22% | Hisse senetleri |
| Elmind Capital, LP | $1.063.628 | 32.037 | 0,20% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $1.000.250 | 30.128 | 0,19% | Hisse senetleri |
| Trexquant Investment LP | $917.515 | 27.636 | 0,17% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $909.116 | 27.383 | 0,17% | Hisse senetleri |
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 09 Ekim 2018 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 30 içeriden öğrenenler · 16 yöneticiler · 15 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Jane Chung | Chief Executive Officer | 04 Mart 2026 M | 21.285 | 1 | 0 | $10.000 |
| William J Newell | CEO | 05 Mart 2025 M | 292.531 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 02 Haziran 2026 M | 4.725 | 1 | 0 | $15.998 |
| Edward C Albini | CFO AND SECRETARY | 15 Mayıs 2025 M | 160.805 | 0 | 0 | $0 |
| Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | 18 Eylül 2026 M | 12.367 | 1 | 0 | $13.600 |
| David Pauling | Chief Admin. Ofcr. & GC | 04 Mart 2026 M | 9.748 | 1 | 0 | $10.003 |
| Barbara Leyman | Chief Business Officer | 08 Temmuz 2025 M | 16.056 | 0 | 0 | $0 |
| Venkatesh Srinivasan | CHIEF TECH OP OFFICER | 01 Mayıs 2025 M | 53.686 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | CHIEF MEDICAL OFFICER | 01 Mayıs 2025 M | 97.452 | 0 | 0 | $0 |
| Linda A Fitzpatrick | CHIEF PEOPLE & COMM. OFFICER | 01 Mayıs 2025 M | 119.744 | 0 | 0 | $0 |
| Nicki Vasquez | CHIEF PORT. STRAT & ALNCE OFCR | 29 Ocak 2024 M | 14.279 | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28 Ağustos 2023 S | 0 | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14 Nisan 2023 M | 100.368 | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 03 Mart 2023 M | 40.827 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 05 Mart 2022 M | 37.736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29 Ocak 2019 A | · | 0 | 0 | $0 |
| Heidi Hunter | Yönetim kurulu üyesi | 05 Haziran 2026 A | · | 0 | 0 | $0 |
| Michael Dybbs | Yönetim kurulu üyesi | 05 Haziran 2026 A | · | 0 | 0 | $0 |
| Jon Marc Wigginton | Yönetim kurulu üyesi | 05 Haziran 2026 A | · | 0 | 0 | $0 |
| Sukhi Jagpal | Yönetim kurulu üyesi | 05 Haziran 2026 A | · | 0 | 0 | $0 |
| Joseph M Lobacki | Yönetim kurulu üyesi | 05 Haziran 2026 A | · | 0 | 0 | $0 |
| Daniel H Petree | Yönetim kurulu üyesi | 05 Haziran 2026 A | 18.601 | 0 | 0 | $0 |
| Connie Matsui | Yönetim kurulu üyesi | 05 Haziran 2026 A | 50.000 | 1 | 0 | $40.000 |
| James P Panek | Yönetim kurulu üyesi | 05 Haziran 2026 A | · | 0 | 0 | $0 |
| John Gordon Freund | Yönetim kurulu üyesi | 06 Haziran 2024 A | 56.327 | 0 | 0 | $0 |
| Shalini Sharp | Yönetim kurulu üyesi | 06 Haziran 2022 A | · | 0 | 0 | $0 |
| Daniel Janney | Yönetim kurulu üyesi | 17 Haziran 2019 A | 1.944.901 | 0 | 0 | $0 |
| Michael Jay Ross | Yönetim kurulu üyesi | 01 Ekim 2018 C | 18.248 | 0 | 0 | $0 |
| Bryan V Lawlis | Yönetim kurulu üyesi | 26 Eylül 2018 A | · | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% sahip | 01 Ekim 2018 C | 1.726.197 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 16 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 5.891 SH | 02 Ekim 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,18% | 29.395 SH | 02 Ekim 2026 | Günlük |
| IWC · iShares Trust | 0,07% | 53.859 SH | 11 Eylül 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11.715 SH | 19 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91.894 SH | 19 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 21.700 SH | 02 Ekim 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 7.595 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177.152 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 47.358 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,01% | 411.674 SH | 11 Eylül 2026 | Günlük |
| IWO · iShares Trust | 0,00% | 23.235 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 29.448 SH | 11 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501.524 SH | 19 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.670 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.330 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 128.703 SH | 11 Eylül 2026 | Günlük |
STRO Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 20 analist
AL
Medyan hedef
$50.00
+225,7%
6 30,0%
Güçlü Al
12 60,0%
Al
1 5,0%
Tut
1 5,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
13 analist · 2026-10-01Ortalama hedef $47.23 +207,7%
Şimdi
Mevcut fiyat $15.35
Düşük$10.00
Ortalama$47.23
Yüksek$61.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | · |
| TLSI | · | · | · | · | · | · |
| IMRX | · | -5.2 | · | · | -45.3% | · |
| ANIK | $133M | -12.6 | -5.9% | -9.6% | -7.5% | 56.6% |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | · |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | · |
| PALI | $375M | -7.8 | · | · | -25.4% | · |
| GLSI | $300M | -14.7 | · | · | -2159.7% | · |
| QTTB | $43M | 1.4 | · | 55.5% | 200.3% | · |
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 12, 2026